Across TCGA pan-cancer cohorts, USP17L13 RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated USP17L13 data layer.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher USP17L13 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated USP17L13 expression acts as an unfavorable survival marker.
ESCA are the cancer types where USP17L13 RNA most reproducibly stratifies survival.